{"url_path":"/sec/rgpx/8-k/2026-06-11/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1357878/0001472375-26-000167-index.html","accession_number":"0001472375-26-000167","cik":"0001357878","ticker":"RGPX","issuer_name":"REGENEREX PHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1357878/0001472375-26-000167-index.html","primary_entity_key":"0001357878","primary_entity_name":"REGENEREX PHARMA, INC."},"word_count":173,"has_tables":true,"body_markdown":"Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment\nof Certain Officers; Compensatory Arrangements of Certain Officers.\n\n \n\nAs\nof June 5, 2026, the Company has commenced legal proceedings against its former\nChief Financial Officer, Kenneth W. Perry (the \"Former CFO\"), in the\nmatter of *Regenerex Pharma, Inc. v. Kenneth W. Perry*, Smith\nCounty Chancery Court, Case No. 2026-CV-8813. The action seeks recovery of\nfunds and other amounts that the Company alleges are owed to it, as well as\nrelief relating to additional matters arising from the Former CFO's conduct\nduring his tenure with the Company.****\n\n \n\nThe Company is pursuing\nall available legal and equitable remedies, including, without limitation,\nmonetary damages, restitution, disgorgement where applicable, injunctive\nrelief, costs, and such other relief as the Court may deem just and proper. The\nallegations contained in the Company's complaint remain subject to judicial\ndetermination, and no assurances can be given regarding the outcome of the\nlitigation.\n\n \n\nContact:\nRegenerex Pharma, Inc.\n\nCompany\nPh: 877-761-RGPX (7479)\n\nInvestor\nRelations Ph: (305) 927-5191\n\nEmail: investors@regenerexpharmainc.com\n\nregenerexpharma.com"}